Currently Viewing:
Supplements New Horizons in the Diagnosis and Treatment of Hereditary Angioedema: Overcoming Barriers to Management and Improving Patient Outcomes
Severity of Hereditary Angioedema, Prevalence, and Diagnostic Considerations
Jonathan A. Bernstein, MD
Current and Emerging Therapies to Prevent Hereditary Angioedema Attacks
William R. Lumry, MD
Currently Reading
Economic Burden Limiting Proper Healthcare Delivery, Management, and Improvement of Patient Outcomes
William J. Cardarelli, PharmD

Economic Burden Limiting Proper Healthcare Delivery, Management, and Improvement of Patient Outcomes

William J. Cardarelli, PharmD
Although several new therapies to both treat acute hereditary angioedema (HAE) attacks and provide prophylaxis for patients with recurrent episodes have been introduced in the past several years, HAE remains a disease with a substantial physical, psychosocial, and economic burden to both affected patients and society in general. Not all treatments work for all patients, and research is ongoing to improve HAE diagnosis and selection of therapy for individual patients to optimize outcomes. But the disease has a significant economic impact with high direct and indirect costs, and high charges related to the new therapies developed for patients to reduce symptoms and attack recurrence. Overall, effective management of HAE is often complicated by clinical and economic barriers to optimal patient outcomes that must be overcome to provide the best care possible and prevent future attacks and complications associated with this rare disease.
Am J Manag Care. 2018;24:-S0
The Cost Burden of Hereditary Angioedema

The health burden of hereditary angioedema (HAE) has been well documented with more than 72% of patients reporting that the disease has significantly impacted their quality of life (QOL).1 In fact, approximately 28% of patients with type I/II HAE reported at least 1 attack a week, with an additional 36% reporting attacks at least once a month, 18% reporting attacks every 2 to 3 months, and 18% experiencing attacks less than every 6 months.1 These attacks are extremely painful and are also associated with high mortality.1

However, the impact of both direct and indirect medical costs of HAE can also be substantial and negatively impact patient management and QOL.2 A landmark study by Wilson et al was designed to assess the economic burden associated with both acute HAE attack and costs related to long-term disease management (see Figure 1).3 The study used an Internet-based survey of adult patients with HAE, 18 years or older, conducted from November 2007 to January 2008. Patients were recruited from the US Hereditary Angioedema Association (HAEA) database. These were patients who contacted the HAEA and identified themselves as having HAE or who requested information or membership from the association.

Approximately 2400 patients were recruited and 457 patients met inclusion criteria. Information was requested surrounding characterization of HAE attacks, including severity, affected body areas, and duration. Those studied reported a mean attack rate of 26.9 HAE attacks annually, and 94% surveyed had at least 1 attack in the past year. Patients were also questioned about use of short-term therapy, long-term disease management, and patient costs, including medical resources used and indirect costs associated with travel and childcare. In addition, the standardized Work Productivity and Activity Impairment questionnaire was used to analyze the effect of HAE on individual patient productivity at work.3 Average direct medical costs were $25,884 per patient annually, with nearly 83% ($21,339) of the cost attributed to medical treatment for acute attacks. Routine care outside of acute therapy accounted for approximately $4545 each year. Average annual costs were $14,379 for mild attacks, $26,914 for moderate attacks, and $96,460 for severe attacks.2 Visits to the emergency department (ED) accounted for almost 50% of direct costs, and ED/hospital care comprised 68% of the total costs of care for patients with severe HAE attacks versus only 4% of costs for those with mild attacks.2-4

In terms of indirect costs, 50% of participants reported missing at least 1 day of work due to their most recent attack with an average number of 3.3 missed days. The average cost of lost wages for work absence for a single HAE attack was estimated at $525.2 Assessed by main frequency across the entire survey population, including those nonworkers, the average cost of missed work related to acute HAE attacks was estimated at $3402 per year.3 The long-term cost associated with being unable to continue full-time employment (working less than full time) was $39,693 (total of 75 patients), at an average of $6512 across the total survey population.3 A later review of this study in 2018 determined that if inflation were taken into account, today’s average annual cost per patient with HAE would be approximately $65,000 in 2017 dollars.4

ED care and hospitalization comprise the leading direct cost burdens for patients with HAE. A study by Zilberberg et al examined the epidemiology and outcomes of hospital ED visits for patients with HAE. During the period from 2006 to 2007, there were 5040 HAE-related visits, of which 53.7% (2705) documented HAE as the primary diagnosis (HAE-PD). A total of 2059 visits (40.9%) resulted in the patient being hospitalized. The mean cost of each ED visit was estimated at $1479, with a total cost of $3,727,080 overall for emergency care during the study period.4,5

Another study headed by Zilberberg was designed to assess the burden, epidemiology, and outcomes of hospitalizations of patients with HAE. This analysis covered the epidemiology, use of resources, and discharge destinations of hospitalizations for HAE through the Agency for Healthcare Research and Quality Healthcare Costs and Utilization Project, which took place from 2004 through 2007. During this time, there were a total of 10,125 hospitalizations with HAE, of which 3216 hospitalizations (31.8%) documented HAE-PD. Of total patients included, approximately 66% were female and 60% were white. The most common comorbidity seen was hypertension, affecting 26.9% of all patients with HAE, and 28.0% with documented HAE-PD with a mortality of 1.4% for the HAE cohort and 0.3% for those with HAE-PD. Mean hospital length of stay was 3.7 days for those with HAE-PD (range of 3.0 to 4.4 days) compared with a mean of 5.0 days (range of 4.6 to 5.4 days) for those in the HAE group. Results demonstrated mean costs of $4760 (range of $3612 to $5907) for those in the HAE-PD group versus $8383 (range of $7432 to $9334) in the HAE cohort. More than 80% of patients in both study groups were discharged routinely to their homes; however, 15.9% of those with HAE versus 4.9% with HAE-PD required discharge to either home-based healthcare or needed transfer to either another short-term hospital or a skilled nursing facility for follow-up care. HAE hospitalization volume is substantial. The investigators also noted that because diagnostic uncertainty with HAE is common, the actual related resource use and cost presented in these data may be underestimated.6

Another study by Lumry et al, assessing the burden of HAE on health-related QOL, including patient productivity, found that mean overall work impairment, calculated as a combination of missed workdays in the previous week and overall reduced productivity, totaled 33.6%. Workers lost a mean 3.3 working days related to their most recent HAE attack, and students lost a mean 1.9 days of school. Nearly 70% of patients stated that HAE was a barrier to them performing certain jobs and approximately 58% believed that HAE had negatively impacted their career advancement.7

HAE Therapy: The Cost Factor

The development of new, disease-specific therapies to treat HAE has revolutionized patient management; however, the costs of these treatments are high.8 The development of new drugs for treatment of HAE was made possible by the orphan drug policies now available in the United States and the European Union. Under the US Orphan Drug Act, a drug is given orphan designation if the disease it treats affects fewer than 200,000 persons or if there is not a reasonable expectation of profitability for the agent.8,9 Some incentives provided for manufacturers of orphan drugs include tax credits toward research costs, clinical research grants, and a 7-year exclusivity toward marketing approved orphan agents.8 While the cost per patient to treat an orphan disease is often substantial, the perception that overall costs to treat rare disease in general has an unreasonable impact on total drug expenditures and healthcare costs is erroneous. Data from both the United States and the European Union have demonstrated a minimal impact related to orphan drug costs and shown them to be in line with the 8% to 10% disease prevalence in these populations studied. In fact, in 2014, total expenditures for pharmaceutical agents in the United States comprised only 9.8% of the $3.0 trillion in total healthcare costs. Expenses for orphan drugs for rare disease indications were estimated at approximately $33.5 billion, which were less than 10% of total pharmaceutical expenditures and only 1% of the total healthcare expenses.8,10,11

However, it remains that the costs for newer agents to treat HAE are substantial. For example, an analysis by Tilles et al showed that the cost of 1 form of C1 esterase inhibitor (C1-INH) approved for HAE prophylaxis and used at appropriate intervals was estimated at $487,000 per patient in 2012. It must be noted that third-party insurers/payers often counteract these costs with shifts to coinsurance models. In the case of some agents, even a 10% coinsurance requirement for patients with HAE could cost as high as a $50,000 annual out-of-pocket expense for a drug such as this one. However, that scenario has been countered and avoided by assistance programs funded by the pharmaceutical companies that manufacture drugs for HAE.12 Current average wholesale prices for treatments for acute HAE attacks can range from $5000 to $10,000 per each attack. The costs are generally higher in the United States because national health systems outside of this country are usually able to obtain these vital drugs at a lower cost.8

An analysis in 2015 determined that the drug costs for HAE had tripled in a 2-year period. Patients were found to be accruing specialty drug treatment costs of more than $300,000 per year. Among commercially insured members of health plans analyzed, 212 members used an HAE drug, leading to higher than $69 million in HAE drug costs that averaged $325,675 in costs per member. Just 23 people among 12.5 million commercially insured members incurred more than $1.0 million in costs for HAE drugs. A total of 66% of HAE drug costs ($45,385,602) were paid via the medical benefit, with 34% ($23,656,387) paid through the pharmacy benefit. Per-member per-month (PMPM) cost of HAE drugs increased a total of 191% from $0.11 in the first quarter of 2012 to $0.32 PMPM in just the first 3 months of 2014 alone. These increased costs were partially driven by a notable increase in the number of members using these agents. As an example, in the first quarter of 2012, 45 members received an HAE drug, which later increased to 118 members in the first quarter of 2014, an increase of 162%. Considering these costs, healthcare professionals (HCPs) and case managers must assist patients with HAE in navigating their medical and pharmacy benefits, and help them to better understand their individual HAE drug utilization to enhance optimal disease management and outcomes.13

Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up